Association of the bevacizumab pharmacokinetics with efficacy and toxicity in advanced non-squamous non-small cell lung cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) 1003 study.

Sho Saeki,Jiichiro Sasaki,Shinya Sakata,Ryo Sato,Koichi Saruwatari,Yasumiko Sakamoto,Megumi Inaba,Hiroto Kishi,Shinji Fujii,Shinsuke Tsumura,Mayu Ouchi,Hideyuki Saito,Akinobu Hamada,Hirotsugu Kohrogi

Association of the bevacizumab pharmacokinetics with efficacy and toxicity in advanced non-squamous non-small cell lung cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) 1003 study.

2017

Sho Saeki
Jiichiro Sasaki
Shinya Sakata
Ryo Sato
Koichi Saruwatari
Yasumiko Sakamoto
Megumi Inaba
Hiroto Kishi
Shinji Fujii
Shinsuke Tsumura
Mayu Ouchi
Hideyuki Saito
Akinobu Hamada
Hirotsugu Kohrogi

e20559Background: Biomarkers predicting the efficacy and toxicity of bevacizumab (Bev) have not yet been established. Therefore we conducted this pharmacokinetic study to elucidate the role of plas...

Keywords:

Bevacizumab
Squamous non-small cell lung cancer
Pathology
Thoracic Oncology
Toxicity
Oncology
Internal medicine
Medicine
Pharmacokinetics
non small cell
Lung cancer
non squamous
Biomarker (medicine)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations